BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
August 2, 2024 12:19 PM EDTCiti analyst David Lebowitz lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $45.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "BridgeBio announced 2Q24 earnings, provided an update on its pipeline, and pointed toward key recent achievements. Mgt. also highlighted... More



